key: cord-0962531-6mpfqw7b
authors: Evangelou, Kyriacos; Rozani, Sofia; Tsagkaris, Christos
title: Monoclonal antibodies as a trick or treat for COVID‐19? The example of abciximab
date: 2022-01-11
journal: J Med Virol
DOI: 10.1002/jmv.27573
sha: d265963d69d6766a8bbdc2249aee583908947cca
doc_id: 962531
cord_uid: 6mpfqw7b

Monoclonal antibodies are antibodies highly monospecific for a particular antigen or an epitope, with a broad spectrum of clinical and experimental uses including autoimmune disease, cancer, bacterial and viral infection, asthma, atopic dermatitis and osteoporosis treatment. 2 So far, five monoclonal antibodies with neutralizing action against epitopes of the SARS-CoV-2 spike protein have been approved for the treatment of COVID-19, namely bamlanivimab, casirivimab, etesevimab, imdevimab and sotrovimab. 3 Nevertheless, COVID-19 detection and treatment has also been reported to overlap with the administration of other monoclonal antibodies aimed towards the management of thrombotic events. As a matter of fact, we deploy the example of abciximab to highlight the importance of retaining pragmatism apropos of ground-breaking treatment options. 4 This article is protected by copyright. All rights reserved.

The medical community should always "do good or do no harm" and owes to spread awareness that everything comes with a price when imprudently used. Ultimately, a crucial question arises as food-for-thought and mental stimulation; will monoclonal antibodies solely avail in treating COVID-19 and preventing serious disease, or simultaneously trick us into considering monoclonal antibody-induced pathologies as viral infection

Covid-19: UK approves first monoclonal antibody treatment

National Institute of Diabetes and Digestive and Kidney Diseases. Monoclonal antibodies. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases

Anti-SARS-CoV-2 Monoclonal Antibodies. National Institutes of Health

Be aware of misdiagnosis tied to COVID-19 focusing: a case report of abciximab-induced alveolar haemorrhage thought to be SARS-CoV-2 in a patient with STsegment elevation myocardial infarction

Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19

Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation

Bleeding events with abciximab in acute coronary syndromes without early revascularization: an analysis of GUSTO IV-ACS

Emergence of SARS-CoV-2 resistance with monoclonal antibody therapy